HealthyWay Inc. disclosed a revised deployment plan for the HK$106.69 million of unutilised proceeds from its December 2024 IPO after identifying mis-stated figures in a 10 June 2026 filing.
Key corrections and new allocations • Total gross proceeds from the 2024 listing remained at HK$109.40 million, of which HK$2.71 million has been spent to date, leaving HK$106.69 million unallocated. • The company will now channel: – HK$36.65 million (33.4% of remaining funds) to accelerate development and commercial roll-out of proprietary AI “digital employee” technologies across health and medical services. – HK$28.00 million (26.3%) to build a nationwide ecosystem for corporate and digital marketing services, including the planned creation of 10–20 regional operating entities in multiple provinces. – HK$22.97 million (21.5%) for strategic acquisitions focused on health-product and healthcare-service providers that offer data, AI, real-world study or ancillary medical capabilities. – HK$14.69 million (13.8%) for research and development, mainly licences, cloud-computing capacity and other infrastructure supporting AI technology advancement. – HK$4.38 million (4.1%) retained for working capital and general corporate purposes.
Rationale for shift 1. Rapid progress in AI: Since 2025 the group’s self-developed AI digital employee suite—covering AI sales assistants, medical assistants and health managers—has shown early commercial traction, reducing the need for large-scale hiring of on-site health assistants, medical experts and business-development staff originally budgeted in the prospectus. 2. Specialty-pharmacy headwinds: Offline pharmacies recorded lower gross margins (9.23% in 2025 vs 10.21% in 2024) amid intensifying competition and sector consolidation. Two underperforming stores were closed in 2H 2025, prompting a pause in further brick-and-mortar expansion. 3. Prudent capital use: No suitable targets have been identified for previously planned acquisitions; focus shifts to opportunities aligned with AI, data and healthcare services.
Strategic consistency The board stated that reallocating funds toward technology-enabled service delivery and higher-growth health-care segments aligns with the company’s original strategy of enhancing operational efficiency, scaling its healthcare platform and maximising long-term profitability. All other information in the 10 June 2026 announcement remains unchanged.